BioCentury
ARTICLE | Clinical News

Melapuldencel-T: Phase I data

April 7, 2014 7:00 AM UTC

An open-label, Chinese Phase I trial in 8 patients with HCC showed that once-weekly subcutaneous TC-DC plus GM-CSF for 3 weeks following standard tumor resection and transarterial chemoembolization (TACE) did not lead to any adverse events related to the injection site. There was 1 serious adverse event of pre-treatment tumor recurrence and no laboratory abnormalities were reported. Cellular Biomedicine said it plans to start a Phase II trial with TC-DC to treat HCC, but declined to disclose a time frame for when the trial will start. ...